An offering of 2,360 shares of Series B preferred stock has pulled in $2 million for Delcath Systems, a company that is developing a system for delivering high dose chemotherapy to the liver. The proceeds will be used to support the company's general corporate functions.
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.